×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BBIO – bridgebio pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
01:00 am
bbio
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Low
Report
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
1/15
11:32 am
bbio
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
Low
Report
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
1/15
06:21 am
bbio
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
Low
Report
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
1/14
04:10 pm
bbio
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]
Low
Report
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]
1/14
04:01 pm
bbio
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Low
Report
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
1/12
05:02 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/12
10:30 am
bbio
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
1/9
10:31 am
bbio
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]
Low
Report
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
09:02 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Jan 08 Filed by: Kumar Neil
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Jan 08 Filed by: Kumar Neil
1/12
04:07 pm
bbio
Form 8-K BridgeBio Pharma, Inc. For: Jan 12
Medium
Report
Form 8-K BridgeBio Pharma, Inc. For: Jan 12
1/8
04:23 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Medium
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
1/8
04:23 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Medium
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
12/16
06:27 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Kumar Neil
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Kumar Neil
12/16
06:26 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Trimarchi Thomas
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Trimarchi Thomas
12/16
06:24 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Apuli Maricel
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 12 Filed by: Apuli Maricel
12/15
04:24 pm
bbio
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Low
Report
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
26.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
TOP News Decliners
3/12
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
-16.6%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: